BMS’s Sprycel (dasatinib) sBLA Receives Positive Response from the US FDA

 BMS’s Sprycel (dasatinib) sBLA Receives Positive Response from the US FDA

BMS’s Sprycel (dasatinib) sBLA Receives Positive Response from the US FDA

Shots:
  •  This sBLA involves (Sprycel + CT) for the treatment of pediatric patients (≤17yrs) newly diagnosed with Philadelphia chromosome +ve ALL
  • The application is based on the ongoing P-II CA180-372 (NCT01460160) trial evaluating (Sprycel + CT) modeled on a Berlin-Frankfurt-Munster high-risk backbone in patients with Ph+ ALL
  •  Expected Action date by FDA is Dec 29, 2018. Though, Sprycel received expanded approval from FDA and EU for Ph+ CML in Nov 2017 and July 2018
Click here to read full press release/ article | Ref: Bristol-Myers Squibb | Image:  Logo Discovery

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post